CLINICAL STUDY

Immunohistochemical staining is not overexpressed in intracellular compartments in thyroid and breast cancers

Isabelle Peyrottes, Valerie Navarro, Alejandro Ondo-Mendez, Didier Marcellin, Laurent Bellanger, Robert Marsault, Sabine Lindenthal, Francette Etette, Jacques Darcourt and Thierry Pourcher

Department of Pathology, Center Antoine Lacassagne, 06100, Nice, France, 1TIRO, CEA DSV-iBEB-SBTN, CAL, School of Medicine, University of Nice Sophia Antipolis, 28, Avenue de Valombreuse, 06107 Nice, France, 2Laboratory of Biophysics, CIE, University of Colombia, Bogota, Colombia and 3CEA center of Marcoule, DSV-iBEB-SBTN, Bagnols-sur-Cèze, France

(Correspondence should be addressed to T Pourcher; Email: pourcher@unice.fr)

Abstract

Objective: The active transport of iodide into thyroid cells is mediated by the Na⁺/I⁻ symporter (NIS) located in the basolateral membrane. Strong intracellular staining with anti-NIS antibodies has been reported in thyroid and breast cancers. Our initial objective was to screen tumour samples for intracellular NIS staining and then to study the mechanisms underlying the altered subcellular localization of the transporters.

Methods: Immunostaining using three different anti-NIS antibodies was performed on paraffin-embedded tissue sections from 93 thyroid or breast cancers. Western blot experiments were carried out to determine the amount of NIS protein in 20 samples.

Results: Using three different anti-NIS antibodies, we observed intracellular staining in a majority of thyroid tumour samples. Control immunohistochemistry and western blot experiments indicated that this intracellular staining was due to non-specific binding of the antibodies. In breast tumours, very weak intracellular staining was observed in some samples. Western blot experiments suggest that this labelling is also non-specific.

Conclusions: Our results strongly indicate that the NIS protein level is low in thyroid and breast cancers and that the intracellular staining obtained with anti-NIS antibodies corresponds to a non-specific signal. Accordingly, to increase the efficiency of radiotherapy for thyroid cancers and to enable the use of radioiodine in the diagnosis and therapy of breast tumours, improving NIS targeting to the plasma membrane will not be sufficient. Instead, increasing the expression level of NIS should remain the major goal of this field.

European Journal of Endocrinology 160 215–225

Introduction

The sodium–iodide symporter (NIS) is the key protein responsible for the transport and concentration of iodide from the blood into the thyroid gland. The rat NIS sequence was the first to be identified followed by the human and mouse sequences. NIS (also called SLC5A5), a member of the sodium/solute symporter family, is an integral membrane protein that resides in the basolateral membrane of thyroid epithelial cells (for review see (4)). Predicted and experimental data indicate that the protein is organized into 13 membrane-spanning domains and contains three N-linked carbohydrates. NIS catalyzes the accumulation of iodide from the blood into the thyrocytes through the basolateral membrane. Once in the cell, the iodide is translocated across the apical membrane into the follicular lumen, where it is immediately organified into thyroglobulin, the thyroid hormone precursor. NIS is also expressed in other organs such as the lactating mammary gland, the salivary gland and the stomach, where it catalyzes iodide accumulation.

For decades, the NIS-mediated iodide accumulation observed in thyrocytes has been an useful tool for the diagnosis (thyroid scintiscan) and treatment (radiotherapy) of various thyroid diseases. Most thyroid cancers are associated with a decreased iodide accumulation capacity appearing as ‘cold’ nodules. Following the identification of the human NIS cDNA, as reported by several groups (6–14), it is now well established that thyroid cancer cells have lower NIS mRNA levels than normal tissues, explaining the decreased iodide uptake. Several early publications reported a lower level of
NIS protein expression in thyroid tumours (15–17), confirming the expected correlation between low levels of NIS mRNA, NIS protein and iodide accumulation. Later, two groups reported results from immunohistochemistry experiments suggesting that the protein is overexpressed in a majority of thyroid cancers or in non-functioning benign thyroid nodules, but that the protein, instead of being located at the basolateral membrane, is predominantly intracellular (18–21).

It has been established that NIS expression is also induced in the mammary gland during lactation (3, 22, 23). Iodide uptake was also detected in non-lactating mammary glands in particular cases (24). Further, Tazebay and collaborators observed that 80% of breast tumours exhibited intracellular staining with anti-NIS antibodies (22). In another study, staining with anti-NIS antibodies was detected in a majority of breast tumours and other carcinomas (19). These authors proposed that NIS is expressed in breast tumours, but that defective targeting of the protein to the plasma membrane leads to the non-existent or low transport capacities.

A better understanding of the molecular mechanisms involved in the iodide transport capacity and post-transcriptional regulation and targeting of the NIS protein in thyroid cancer cells would likely be useful for improving $^{131}$I radioablation therapy. In addition, increasing NIS expression in breast cancer cells may allow the use of iodide transport for the diagnosis and treatment of these tumours and related metastases. This work was initiated with the goal of obtaining, from our tissue bank, biological material for further studies in which the NIS protein is not correctly located at the plasma membrane. For this purpose, we analyzed the NIS expression in surgical tissue specimens from patients with various thyroid pathologies or breast cancers.

Materials and methods

Patients

All the samples were selected after histological examination and classified according to the World Health Organization recommendations (25). The immunohistochemistry (using three anti-NIS antibodies) included 72 patients who underwent surgery for different thyroid pathologies (Table 1): 9 Graves’s disease; 16 adenomas; 27 papillary carcinomas; 15 follicular carcinomas; and 5 medullary carcinomas. Several samples of normal thyroids (from patients who underwent surgery for other pathologies) were also used for control experiments. Additional samples were used for the western blot analysis: 8 Graves’s disease (as positive controls) and 11 papillary carcinomas. The same samples were also studied using immunohistochemistry using one anti-NIS antibody. The results (data not shown) were similar to those of Table 1. Patients were living in the region of the city of Nice, an iodine-sufficient area. Thirty samples of ductal breast cancers (ten of each grade (I, II and III)) were used for the immunohistochemical analysis and nine out of these samples for immunoblot analysis. Surgical tissue specimens were dissected and several tissue samples prepared. For histological studies of the tumours, the isolated samples included both tumour tissue and surrounding normal tissue. The tissues were fixed in 10% formalin and embedded in paraffin. For immunoblot analysis, tumour samples were carefully dissected and all normal tissue was removed. Samples of surrounding normal tissue were also prepared. Tissue samples were quickly frozen and stored in liquid nitrogen.

**Antibodies**

The primary monoclonal anti-NIS antibody 39S (Ab 39S anti-NIS) was obtained by immunizing mice with purified human NIS protein and fusion of their splenocytes with a mouse myeloma cell line (ATCC#CRL-1580) according to the standard protocols (26). The epitope recognized by the 39S antibody is located between amino acids 580–600 (data not shown). The mouse monoclonal anti-NIS antibody Ab-1 (NeoMarkers, Fremont, CA, USA), clone FP5A, was purchased from Interchim (Montlucon, France). The FP5A antibody recognizes a peptide corresponding to amino acids 625–643 (17). These two antibodies are

<table>
<thead>
<tr>
<th>Diagnosis of thyroid scan</th>
<th>Number of patients</th>
<th>Membrane staining</th>
<th>Cytoplasmic staining</th>
<th>Membrane and cytoplasmic staining</th>
<th>No staining</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graves’ disease</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Oncocytic adenomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cold</td>
<td>6</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Hot</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Non-oncocytic adenomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cold</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Hot</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Papillary carcinomas</td>
<td>27</td>
<td>0</td>
<td>15</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>Follicular carcinomas</td>
<td>15</td>
<td>0</td>
<td>9</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Medullary carcinomas</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

Table 1 Anti-NIS antibody staining in thyroid cancers.
specific for NIS, as shown in western blot experiments performed on membrane proteins from NIS-expressing cells. The 39S and FP5A antibodies reveal a major band with a molecular weight of ~90 kDa, corresponding to the fully glycosylated protein, as well as additional minor bands (see Dayem and collaborators for the 39S antibody (27) and Castro and collaborators for the FP5A antibody (17)). The mouse monoclonal anti-NIS antibody VJ1 (28), obtained by genetic immunization, was a generous gift from Dr Costagliola (IRIBHN, Brussels, Belgium). The epitope recognized by the VJ1 antibody is not well defined, but is presumably located at the cell surface and probably, as has been proposed for VJ2, contains amino acids located within the last extracellular loop (28). This antibody does not recognize denatured NIS protein following SDS-PAGE. For control experiments, a monoclonal anti-CD45 antibody (clone 2B11 from Dako France, Trappes, France) and an oestrogen receptor (ER) antibody (clone 2B11 from Dako France, Trappes, France) was used at a 1:5000 dilution for FP5A, and at a 1:150 dilution for VJ1 Ab. For control experiments, a monoclonal anti-CD45 antibody (Clone 2B11 from Dako France, Trappes, France) was used at a 1:300 dilution. For ER immunostaining, a diluted preparation of clone SP1 from Ventana, Illkirch, France were used.

**Immunohistochemistry**

The tissues were fixed in 10% formalin and embedded in paraffin. Sections (2.5 μm thick) were deparaffinized, rehydrated and immunostained using an automated immunostainer (Benchmark XT, Ventana Medical Systems) with standardized duration and temperature for all steps. Endogenous peroxide and biotin activities were blocked using the Ventana iVIEW™ inhibitor. The tissues were fixed in 10% formalin and embedded in paraffin. Sections (2.5 μm thick) were deparaffinized, rehydrated and immunostained using an automated immunostainer (Benchmark XT, Ventana Medical Systems) with standardized duration and temperature for all steps. Endogenous peroxide and biotin activities were blocked using the Ventana iVIEW™ inhibitor. The sections were blocked according to the standard protocol from Ventana. The blocking agents are goat IgG and casein. After pre-treatment, slides were incubated for 32 min at 37 °C with one of the three anti-human NIS antibodies at concentrations of 3 μg/ml for 39S Ab and 0.2 μg/ml for hNISAb-1 (FP5A), and at a 1:150 dilution for VJ1 Ab. For control experiments, a monoclonal anti-CD45 antibody (Clone 2B11 from Dako France, Trappes, France) was used at a 1:300 dilution. For ER immunostaining, a diluted preparation of clone SP1 from Ventana was employed. Immunostaining of all the samples was performed with a Basic DAB Detection kit (Ventana Medical Systems), following the standard protocol. After washing, all slides were counterstained with haematoxylin. In each case, serial slides were stained with haematoxylin–eosin for histological evaluation. Image acquisition was performed using an Olympus DX52 microscope (Olympus France, Rungis, France) equipped with an Olympus DP70 Camera.

**Preparation of membrane vesicles**

All the preparations were carried out at 4 °C. Samples of human thyroids (100–200 mg) or breasts (100–300 mg) were thawed in 250 mM sucrose, 10 mM HEPES–KOH (pH 7.5), 10 mM NaCl, 1 mM CaCl₂, 1 mM MgCl₂, 1 mM EDTA (1–1.5 ml per 50 mg tissue) and mammalian protease inhibitors (Complete, Roche Diagnostics), and disrupted with a motor-driven Tellon pestle homogenizer (1000 rpm/min). The homogenate was centrifuged at 1000 g for 10 min at 4 °C to eliminate cellular debris. The supernatant was removed and centrifuged at 10 000 g for 10 min at 4 °C and the supernatant of this centrifugation was centrifuged at 100 000 g for 1 h at 4 °C. The pellet (MV) was suspended in 100 μl cold 100 mM mannitol, 10 mM HEPES–KOH (pH 7.5), 10 mM NaCl, supplemented with a mammalian protease inhibitor cocktail (Complete, Roche Diagnostics), and stored at −80 °C.

**Western blot analyses**

Thyroid samples (80 μg membrane protein) were mixed with 2× loading buffer (Sigma–Aldrich) and incubated for 40 min at 42 °C prior to electrophoresis. Proteins were separated on SDS/PAGE (4–15% Ready Gel Precast Gels, Bio-Rad) and transferred to a PVDF membrane (Hybond-ECL, GE healthcare, Saclay, France). Membranes were saturated for 45 min in blocking buffer (PBS, 2 g/l casein from 1-Block, Tropix, Bedford, MA, USA) and then incubated for 2 h at room temperature with the primary antibody. Subsequently, membranes were washed thrice for 10 min in PBS buffer and incubated with the secondary antibody (an HRP-linked goat anti-mouse IgG (Pierce-Perbio, Brebières, France; dilution 1:5000) for 45 min at room temperature. Three final washes in PBS buffer were performed. Horseradish peroxidase was revealed by SuperSignal West Pico (Pierce). PVDF membranes were stripped and reprobed with anti-Na⁺/K⁺-ATPase MAB (Clone 464.6 from Novus Biologicals, Littleton, CO, USA) or anti-cadherin pan polyclonal antibody (AnaSpec Inc., San Jose, CA, USA) as plasma membrane protein markers.

**Results**

**Immunohistochemistry in normal thyroid tissues**

All our study was carried out with three monoclonal anti-NIS antibodies to avoid potential non-specific immunoreactivity. These antibodies recognize three different epitopes on the human NIS protein. As reported in many studies, heterogeneous anti-NIS antibody staining was obtained in follicular epithelial cells of the normal thyroid. The FP5A antibody staining is shown in Fig. 1A; the same pattern was obtained using the 39S or VJ1 antibodies (data not shown). Only a few cells showed positive staining. In these positive cells, the NIS protein was confined to the basolateral membrane.
No intracellular anti-NIS antibody staining was observed. Most of the cells did not show any labelling. These unlabeled cells were flat and presumably correspond to non-stimulated cells. In all the experiments on thyroid adenomas or carcinomas described above, the normal surrounding tissue was also examined and was used as an internal control for the immunolabelling of each section. This analysis was not only a control for the staining procedure but also expected to ensure the homogeneity of the patients with regard to other factors (i.e. iodide supply (29)) that could modify the NIS expression in the thyroid.

Immunohistochemistry in thyroid tissues corresponding to Graves’ disease

Homogeneous anti-NIS antibody labelling was obtained in follicular epithelial cells from thyroids of patients with Graves’ disease. Almost, all the cells showed strong positive staining confined to the basolateral membrane. The same pattern was obtained with the 39S (Fig. 1B), FP5A (Fig. 1C) and VJ1 (Fig. 1D) antibodies. However, when we compared serial sections from a single sample (as shown in Fig. 1B–D), the labelling was stronger but more spread out with the 39S antibody. For each set of
experiments described below, a thyroid section corresponding to Graves’ disease was used as a positive control.

**Immunohistochemistry in thyroid adenomas**

The selection of thyroid adenomas was based on histological examination. Selected samples were classified into two groups: samples that contained oncocytic cells (also called ‘Hürthle cells’), and those that did not. The oncocytic nature of the cells was revealed by an abundant and faintly granular cytoplasm and a large nucleus with prominent nucleolus upon haematoxylin–eosin staining (compare Fig. 1E with F). Based on this classification, the immunohistochemistry experiments were carried out. In the first group, which included seven thyroid adenomas with oncocytic cells, strong intracellular staining was observed in five adenomas (illustrated in Fig. 1H). One of them also exhibited staining of both the cytoplasm and the basolateral membrane. This adenoma was previously characterized after thyroid scintiscan using $^{99m}$TcO$_4$ and corresponded to hyperfunctioning adenomas (toxic adenomas). In the second group, which included nine thyroid adenomas without oncocytic cells, the cells were similar to normal cells (Fig. 1E). Four samples exhibited positive anti-NIS antibody staining of the basolateral membrane (Fig. 1G); all were previously characterized after thyroid scintiscan and corresponded to toxic adenomas. No staining was observed in the five other adenomas. These adenomas were characterized by scintiscan imaging and all corresponded to hypofunctioning areas.

**Immunohistochemistry in thyroid papillary carcinomas**

Two sets of experiments were carried out with thyroid papillary carcinomas. In the first set of 16 papillary carcinomas, we observed intracellular anti-NIS antibody staining in eight samples (illustrated in Fig. 2A). The other eight papillary carcinomas did not show any anti-NIS antibody staining (illustrated in Fig. 2B). Next, we decided to exclude papillary carcinomas that contained cells with oncocytoid features (characterized only by an abundant and faintly granular cytoplasm) in the second set of experiments. Eleven new carcinomas were chosen. In 7 out of the 11, NIS-staining localized to the cytoplasm was observed (illustrated in Fig. 2C). However, the NIS-labelling intensities were lower than those obtained with the first set of specimens (compare Fig. 2A and C).

**Immunohistochemistry in follicular carcinoma**

In 9 out of the 15 follicular carcinomas, we observed intracellular anti-NIS antibody staining (Fig. 2D and E). The intracellular staining was granular. No staining of the basolateral membrane was detected.

**Immunohistochemistry in medullary carcinomas**

None of the five medullary carcinomas showed anti-NIS antibody staining.

**Immunohistochemistry in thyroid tissues corresponding to Hashimoto’s disease**

Immunoreactivity with the same anti-NIS antibodies was also analyzed in the thyroids of several patients with Hashimoto’s disease. Anti-NIS antibody staining was confined to a few follicles. In these cells, the staining was clearly intracellular but not intense. We noted that these cells corresponded to oncocytic metaplasias surrounding lymphocyte infiltrations (Fig. 2H).

**The immunohistochemistry pattern observed with anti-NIS antibodies was also obtained with other antibodies and was also found in hepatocytes**

As the anti-NIS antibody staining was repeatedly linked to the oncocytoid appearance of the cells, we postulated that the anti-NIS antibody labelling could be due to non-specific binding of our anti-NIS antibodies. Therefore, we studied the immunohistochemistry pattern obtained using antibodies directed against other proteins. The first antibody was directed against CD45, a transmembrane protein tyrosine-specific phosphatase (PTPase). The second antibody was directed against the ER. Both proteins are not expressed in thyrocytes. In all the tested samples showing intracellular anti-NIS antibody staining, both antibodies gave rise to similar staining patterns. One example is illustrated in Fig. 2E–G. In this follicular carcinoma, similar intracellular staining was obtained with anti-NIS, anti-CD45 and anti-ER antibodies. In addition, we observed intracellular anti-NIS antibody staining in hepatocytes (Fig. 2I) that have oncocytoid features (i.e. abundant mitochondria) and are not expected to express NIS. These results indicated that the intracellular anti-NIS staining observed in thyroid cancers is not related to the specific binding of the antibody or to NIS overexpression.

**Western blot analysis of thyroid samples**

Western blots were performed to determine the level of NIS protein in thyroid samples. Only the largest tumours could be used for this analysis. Eleven papillary tumour samples were selected and carefully dissected. A portion of each sample was analyzed by immunohistochemistry using anti-hNIS antibodies. They were included in the above study (Table 1). These samples correspond to...
various intracellular anti-NIS antibody staining behaviours: five did not show staining; in two samples the labelling was low; it was strong in two others and intermediate in the two remaining carcinomas. Surrounding normal tissue was completely removed from the portion of the tumour used for western blots. Membrane fractions were prepared and analyzed. Nine thyroid samples from patients with Graves’ disease were used as positive controls. It is well established that the fully glycosylated hNIS protein migrates with a
molecular weight of ~90 kDa. While a corresponding band was observed with thyroid samples corresponding to Graves’ disease (illustrated in Fig. 3, lanes 4–5), no corresponding bands were observed with the thyroid tumour samples (illustrated in Fig. 3, lanes 1–3). By contrast, a band migrating with a molecular weight of ~50 kDa was observed in the tumour samples (Fig. 3). The 50 kDa band is believed to correspond to partially glycosylated NIS protein as already demonstrated (30, 31). Further, an additional, strong 15 kDa band was present in thyroid samples corresponding to Graves’ disease. This 15 kDa band was also present in most thyroid cancer samples (Fig. 3). We did not observe any relationship between the intensities of the 90, 50 and 15 kDa bands and the intracellular staining. These results corroborated that the intracellular anti-NIS staining in thyroid cancers is not related to specific binding of the antibody or to NIS overexpression.

**NIS expression in breast cancers**

The histological grade of breast tumours was assessed by the method of Scarff, Bloom and Richardson (SBR) as modified by Elston and Ellis (32). Ten specimens each of ductal breast cancer tissue of SBR grade I, II or III were studied. Using the same labelling conditions as described above for thyroid samples, immunohistochemical analysis was performed. No significant anti-NIS antibody staining was observed in the 30 breast cancer samples (Fig. 2J). However, some samples did show diffuse and weak anti-NIS antibody staining (Fig. 2K). We, therefore, increased the duration of incubation with the DAB substrate chromogen but these new conditions did not lead to modify our results. We also determined the level of protein expression in nine of these breast tumour samples corresponding to various intracellular anti-NIS antibody staining behaviours. Membrane fractions were prepared and analyzed by western blot. Figure 3 presents results obtained with three representative samples (lanes 6–8). The first is a grade I ductal breast cancer showing no staining with immunohistochemistry. Weak staining in both the plasma membrane and the cytoplasm was observed with the second sample (grade III ductal breast cancer). The third is a grade I ductal breast cancer that showed intracellular staining. For all the breast tumour samples tested, no bands corresponding to the fully glycosylated NIS were observed. As with the thyroid tumours, a 50 kDa band corresponding to partially glycosylated NIS was observed in some breast cancer samples. In addition, a 15 kDa band was also seen in some breast cancer samples; this 15 kDa band was also present in most thyroid cancers. We observed a decrease in a housekeeping plasma protein (Na\(^+\)/K\(^+\)-ATPase) in some of our breast cancer samples (Fig. 3); the reason for this was not evaluated.
this decrease is unknown. The results obtained with the
anti-cadherin pan antibody showed more homogenous
results but differences are still observed between the
three kinds of samples (papillary carcinomas, Graves and
ductal breast cancers). Altogether our results indicated
that the level of NIS expression in breast cancers is very
low and that the fully glycosylated protein is not present.

Discussion

The present study was initiated to identify thyroid and
breast tissue specimens that contained cells expressing
intracellular NIS. Our initial aim was to study the
molecular mechanisms that lead to intracellular NIS
expression. Our results indicate that the intracellular
labelling obtained with the anti-NIS antibodies in
thyroid cancers corresponds to a non-specific signal.
In addition, we did not observe significant intracellular
NIS protein expression in breast cancer samples.

Previous studies have reported that a majority of
thyroid cancer samples display intracellular anti-NIS
antibody labelling (18, 19). These studies used a
polyclonal antibody raised against two peptides from
the C-terminus of hNIS. The authors proposed that the
intracellular expression, or even overexpression, of NIS
occurs in most thyroid cancer cells. Another group
reported the intracellular overexpression of NIS in more
than half of non-functioning benign thyroid nodules
using monoclonal anti-NIS antibody VJ2 (20). We also
observed intracellular labelling in a majority of thyroid
cancer samples using three different monoclonal
antibodies. Together, these observations clearly indicate
that intracellular labelling is observed in most thyroid
tumours using various anti-NIS antibodies.

Oncocytoid cells are characterized by the presence of
abundant granular cytoplasm resulting from the
aberrant accumulation of mitochondria. Oncocytic
cells also show a large nucleus with prominent nucleoli
(illustrated in Fig. 1F). As the intracellular anti-NIS
antibody staining is also granular, we asked whether
this intracellular staining could be related to the
oncocytoid character of the cells. Indeed, five out of
the six adenomas that contained cells with an oncocytoic
appearance showed intracellular labelling. By contrast,
the five cold adenomas without oncocytes did not
show intracellular labelling. Toxic adenomas were
clearly recognized by strong membrane staining but one
sample with oncocytoid cells also showed intracellular
labelling. In papillary carcinomas, we first observed, in
a first set of experiments, strong intracellular staining in 8
out of the 16 samples. But it was difficult to determine
accurately that samples contained more oncocytoic
cells. To overcome this difficulty, we decided to exclude
papillary carcinomas that contained cells with an
oncocytoid appearance in a new set of specimens. We
found intracellular anti-NIS antibody staining in 7 out
of a total of the 11 samples. However, the intensities
were much lower in cells from papillary carcinoma
specimens that did not show an oncocytoid appearance.
We cannot exclude that some cells of these samples have
some oncocytoid behaviours. In addition, intracellular
anti-NIS antibody staining was observed in oncocytic
metaplasia surrounding lymphocyte infiltrations in
thyroid tissues corresponding to Hashimoto’s disease.
Finally, experiments were carried out on hepatocytes
that have oncocytoic features (i.e. abundant mito-
chondria) and are not expected to express NIS. These
cells showed intracellular anti-NIS antibody labelling.
Altogether, our observations suggested that the label-
ing localized to the cytoplasm could be related to the
oncocytoid nature of the tumour cells.

To investigate whether the intracellular anti-NIS
antibody staining correlated with NIS protein
expression, control experiments were carried out with
the same specimens using anti-ER and anti-CD45
antibodies. CD45 is a transmembrane tyrosine phospha-
tase that is abundant in most differentiated haemato-
poietic cells, but is not expressed in normal or tumour
thyroid cells. No specific staining was expected using
anti-CD45 antibodies. ER was also expected to be absent
from thyroid cells, but a recent publication suggests that
ER is expressed in thyroid cancer lines and could
contribute to the development of thyroid carcinomas
(33). A specific immunostaining of ER is expected to
show a different pattern (as nuclear localization).
However, the thyroid cancer samples showed similar
intracellular staining using anti-NIS, anti-ER or anti-
CD45 antibodies. Small differences in the labelling
intensity could be due to variations in the concentration
of the primary antibody used. These experiments
indicated that the observed intracellular anti-NIS
antibody staining is not related to the specific binding
of the antibodies and NIS overexpression. Consequently,
a low level of NIS protein expression was expected in
thyroid cancer samples regardless of whether or not they
showed intracellular staining. Indeed, a low level of
(partially glycosylated) NIS protein was found in all
thyroid tumour samples when analyzed by western blot.
No difference in the protein pattern related to the
presence of intracellular anti-NIS antibody staining
was observed in corresponding immunohistochemistry
experiments. Furthermore, our results suggest that fully
glycosylated NIS protein is not present in thyroid
tumours. By contrast, in the same experiment, a band
corresponding to the fully glycosylated NIS protein was
clearly identifiable in thyroid tissues (corresponding to
Graves’ disease including samples with a number of
stained cells close to normal tissues) that showed plasma
membrane expression of NIS. Partially glycosylated NIS
(50 kDa band) was detected in most of the carcinomas.
Similar observations were reported by Trouttet-Masson
and collaborators (14). They concluded that the
impairment of NIS in thyroid tumours might result
from alterations occurring at the transcriptional and
post-transcriptional levels. They studied two tumours

www.eje-online.org
showing a weak intracellular labelling and concluded that this staining correlated to immature NIS. Other reports have suggested that the NIS protein is highly regulated by post-transcriptional events that control, in particular, its subcellular localization (34–36). Partially glycosylated forms of NIS correspond most probably to immature proteins that are not properly processed to the plasma membrane. It should be mentioned that we used a protocol for the preparation of membrane vesicles only excluding the nuclear envelope but comprising all other subcellular membrane fractions. However, as illustrated in Fig. 3 (compare lanes 1, 2 and 3), our western blot experiments did not allow us to correlate the amount of partially glycosylated protein with the intracellular staining (intensity and number of labelled cells) observed in immunohistochemistry experiments. A smaller 15 kDa band (corresponding to a small fragment of NIS, as determined by sequencing and mass spectroscopy, unpublished data) was also detected in most of the papillary tumours. This 15 kDa band was also more clearly observed in thyroid samples representative of Graves’ disease. Importantly, this 15 kDa band was recognized by only two of the three different anti-NIS antibodies used in this study (unpublished data). As the three antibodies gave rise to similar intracellular staining in thyroid tumour cells, the intracellular labelling could not result from the staining of this NIS fragment. All these data further support the conclusion that the intracellular anti-NIS antibody staining observed in immunohistochemistry experiments is not related to the presence of NIS protein.

Using the same experimental conditions, we did not observe significant staining in breast cancer samples at different SBR grades (I–III). Strong intracellular anti-NIS antibody staining was never observed. These results differ from those published by other groups (19, 22). For example, Tazebay and collaborators proposed, for the first time, that the NIS protein is expressed in breast tumours (22). Intracellular anti-NIS antibody staining was reported in 80% of breast cancer samples. In addition, Wapnir and collaborators (from the same group), using tissue microarrays, found anti-NIS antibody staining in a majority of fibroadenoma and breast tissue samples (19). These authors explained that the observed staining of the cytoplasm made it difficult to discern plasma membrane immunoreactivity. They also reported, using the same conditions and antibodies, intracellular anti-NIS antibody staining in thyroid carcinomas. Using a robot for the labelling procedure, our results were very reproducible within a given set of experiments or between any two sets. For each thyroid cancer sample, the normal tissue surrounding the tumour cells was always studied, and the intensity of the positive staining of normal cells was used as an internal control. For each set of breast cancer samples, at least one thyroid sample was included as a positive control. Nevertheless, our immunohistochemistry analysis showed that, in a majority of breast cancers, NIS expression was low. We observed strong intracellular staining in a majority of thyroid cancer samples, but only few, very weakly labelled cells in breast cancer tissues. The results presented in the recent publication of Beyer and collaborators (37) could partially explain this discrepancy. The authors analyzed 192 invasive ductal breast carcinomas with immunohistochemistry. They used three different anti-NIS antibodies (#442, #836 and VJ1). A similar strong membrane staining confined to the basolateral membrane was observed in thyroid samples corresponding to Graves’ disease using any of these three antibodies. Using #442 affinity purified polyclonal anti-NIS antibodies, intracellular labelling was found in the majority of breast tumours. But, however, using #836 non-purified polyclonal anti-NIS antibodies, intracellular staining was barely detected in breast tumours. Furthermore, using the monoclonal VJ1 antibody, no intracellular staining was found in breast cancers. The authors proposed that the VJ1 epitope is either not accessible due to post-transcriptional modifications or has a different tertiary structure in breast cancers. We used VJ1 in this study and no significant intracellular labelling was observed in breast cancers. We here described the results obtained on 30 breast cancers but according to the data of Beyer and collaborators we should expect the same result with a larger number of samples. In addition, using the 39S and FP5A antibodies, we did not find intracellular staining. Altogether, published results and our observations suggest that the intracellular staining is obtained only with some (preferentially polyclonal) antibodies and therefore could be related to non-specific binding.

In our western blot experiments (Fig. 3), the fully glycosylated protein was undetectable in breast cancer cells. Conversely, partially glycosylated NIS proteins (50 kDa band) and an NIS fragment (15 kDa band) were observed. Although partially glycosylated NIS should be mainly located in the cytoplasm of cells, the amount of partially glycosylated protein was similar in breast cancer cells and in cells from thyroid carcinomas that did not show intracellular staining (Fig. 3). Some reports have shown, however, that breast tumours can express functional NIS and accumulate iodide (38–40). For example, Berger and collaborators showed that functional NIS was expressed in a benign fibroadenoma and was localized to the plasma membrane (38). Further, Thorpe showed more than 30 years ago that iodide uptake is increased in hormone-responsive mouse mammary tumours (41), suggesting that there is functional NIS in breast tumours. In conclusion, we report the study of 30 breast cancer cases (SBR grades I–III). No anti-NIS antibody staining was observed at the plasma membrane by immunohistochemistry. Very weak intracellular staining was, however, detected in a few samples. This staining corresponds probably to low amounts of partially glycosylated NIS, to the NIS fragment (15 kDa band), or to non-specific binding of...
the antibodies. Nevertheless, our conclusion is that NIS expression is very low in breast cancers and that functional NIS expression is rare. Indeed, a recent study showed that the iodide uptake activity seems to be insufficient in clinical practice for imaging breast carcinomas (42). In any case, enhancing NIS expression in breast cancers (43) remains a very promising approach that could allow the use of induced iodide accumulation for the diagnosis and therapy of malignant breast cells.

Wapnir and collaborators, using tissue microarrays, found anti-NIS antibody staining in a majority of extrathyroidal carcinomas (19). The authors conclude that NIS is predominantly expressed intracellularly in many carcinomas. This conclusion should be re-examined considering our results and a non-specific binding of NIS antibodies.

In conclusion, our data cannot exclude the possibility that defective targeting of NIS contributes to the reduced level of iodide uptake observed in thyroid and breast cancers. However, it is clear that the main cause of this defect is low NIS expression, and not the intracellular localization of overexpressed NIS. These conclusions support the expected correlation between mRNA levels, protein expression, and iodide accumulation capacity in thyroid and breast tumours. Our results indicate that increasing the expression level of NIS should thus remain the major goal to enhance the efficiency of radiotherapy for thyroid cancers and to enable the use of radiiodine in the diagnosis and therapy of breast tumours. Improving NIS targeting to the plasma membrane will not be sufficient.

Declaration of interest
The authors have no conflict of interest.

Funding
This work was supported by grants from EDF. A O-M was funded by ECOS-Nord. V N was a recipient of a fellowship funded by the ToxNucE program.

Acknowledgements
The authors thank Magalie Forchino, Fanny Graslin and Olivier Averseng for excellent technical assistance. The authors wish to thank Dr Patrick Chang for critical reading of the manuscript.

References
8 Ryu KY, Senokozlieff ME, Smanik PA, Wong MG, Siperstein AE, Duh QY, Clark OH, Mazaferri EL & Jhiang SM. Development of reverse transcription-competitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter (in process citation). *Thyroid* 1999 9 405–409.
NIS expression in thyroid and breast cancers


41 Thorpe SM. Increased uptake of iodide by hormone-responsive compared to hormone- independent mammary tumors in GR mice. *International Journal of Cancer* 1976 **18** 345–350.


Received 6 November 2008
Accepted 13 November 2008

www.eje-online.org